Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04384770 | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | active not recruiting | — | 179 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 |
| clinicaltrials |
| NCT01368588 | Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 3 | 2,590 | Radiation Therapy Oncology GroupNETWORK | 6 | May 8, 2026 | clinicaltrials |
| NCT03637543 | Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 2 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05826509 | SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer(SUGAR) | active not recruiting | Phase 2 | 240 | Institut Claudius RegaudOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT00579072 | The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older | active not recruiting | — | 230 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT02446444 | Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer(ENZARAD) | active not recruiting | Phase 3 | 802 | University of SydneyOTHER | 9 | May 6, 2026 | clinicaltrials |
| NCT04136353 | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate(DASL-HiCaP) | active not recruiting | Phase 3 | 1,100 | University of SydneyOTHER | 6 | May 6, 2026 | clinicaltrials |
| NCT06212583 | High-Risk Metachronous Oligometastatic Prostate Cancer Trial(KNIGHTS) | active not recruiting | Phase 2 | 88 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01411345 | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial(MAPS) | active not recruiting | N/A | 37 | University of MiamiOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03772834 | Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05851365 | Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer | active not recruiting | Early Phase 1 | 1 | Robert Flavell, MD, PhDOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06651632 | WATER IV Prostate Cancer(WATER IV PCa) | active not recruiting | N/A | 280 | PROCEPT BioRoboticsINDUSTRY | 7 | May 4, 2026 | clinicaltrials |
| NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer(ASCLEPIuS) | active not recruiting | Phase 1 / Phase 2 | 102 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05322356 | Prostate Interstitial Brachytherapy With I125 Implant With Target Dose Supplementation in the Tumor Volume Guided by TRINITY® PERINE 3D System(FOCUS-BOOST) | active not recruiting | N/A | 15 | University Hospital, GrenobleOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04597411 | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 101 | EndocyteINDUSTRY | 2 | Apr 30, 2026 | clinicaltrials |
| NCT07117760 | Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 16 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07553988 | A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 120 | R-Pharm International, LLCINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03436654 | Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma | active not recruiting | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06580015 | [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06326216 | Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer | active not recruiting | — | 98 | Mayo ClinicOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02960087 | Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer | active not recruiting | N/A | 334 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | active not recruiting | Phase 2 | 251 | Cancer Trials IrelandNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04215029 | Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans | active not recruiting | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05047965 | An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer | active not recruiting | Early Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05055843 | Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer | active not recruiting | N/A | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07236112 | Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 6 | C Ray TherapeuticsINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04842890 | Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer | active not recruiting | Phase 2 | 61 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06434649 | Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer | active not recruiting | N/A | 118 | Ning XuOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00859781 | 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | active not recruiting | Phase 2 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03827616 | Moderately Hypofractionated Radiotherapy for Prostate Cancer. | active not recruiting | N/A | 400 | Tatarstan Cancer CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)(AlphaBreak) | active not recruiting | Phase 2 | 110 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07214961 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(ARTISAN) | active not recruiting | Phase 1 | 80 | ARTBIO Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04147806 | A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer(PROSINT) | active not recruiting | Phase 1 | 31 | Albert Einstein College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).(TATCIST) | active not recruiting | Phase 2 | 115 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04357925 | Quality of Life in Prostate Cancer Patients(QoLProstateMQ) | active not recruiting | — | 304 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05266313 | Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy(VITALITE) | active not recruiting | N/A | 135 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 11, 2026source: clinicaltrials